Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients

Breast Cancer Clinical Trial

Official title:

A Pilot Randomized Phase II Study of Adjuvant Administration of Trastuzumab (HERCEPTIN) Versus Observation After the Completion of Adjuvant Chemotherapy and Radiotherapy in Patients With Stage I-III Breast Cancer Who Have Detectable Disseminated and/or Circulating Tumor Cells (DTCs and/or CTCs) in the Bone Marrow or/and the Peripheral Blood Before or/and After the Completion of Adjuvant Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00429247
• Other study ID #: CT/01.60
• Status: Completed
• Phase: Phase 2
• First received: January 30, 2007
• Last updated: July 20, 2011
• Start date: February 2003
• Est. completion date: December 2007

Study information

• Verified date: January 2008
• Source: University Hospital of Crete
• Contact: n/a
• Is FDA regulated: No
• Health authority: Greece: National Organization of Medicines
• Study type: Interventional

Clinical Trial Summary

Epithelial tumor cells can be detected in the bone marrow and/or the peripheral blood [disseminated and circulating tumor cells, (DTCs) and (CTCs) respectively] of otherwise metastases-free patients with early breast cancer. Several studies have shown that the presence of these cells is an independent factor associated with an increased incidence of early disease relapse and disease-related death. In almost 50% of the patients, adjuvant chemotherapy cannot eliminate these occult tumor cells and this is also associated with a higher probability of early relapse and death. In 60-70% of the patients, DTCs and/or CTCs express the HER2/c-neu molecule and one or two administrations of their monoclonal antibody trastuzumab (HERCEPTIN) could eliminate these cells for a period ranging from 3-12 months.

Description:

This pilot trial will compare the efficacy of the anti-HER2/erb-B2 monoclonal antibody trastuzumab (HERCEPTIN) given after the completion of the standard adjuvant chemotherapy and radiotherapy versus observation in patients with stage I-III operable breast cancer who have detectable cytokeratin-19 (CK-19) mRNA-positive tumor cells in the bone marrow or the peripheral blood before and/or after the adjuvant treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: December 2007
• Est. primary completion date: December 2007
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age >= 18 years.

• Performance status (World Health Organization [WHO]) < 3

• Adequate bone marrow function (absolute neutrophil count > 1000/mm^3, platelet count > 100000/mm^3, hemoglobin > 9 gr/mm^3)

• Adequate liver (bilirubin < 1.5 times upper limit of normal and SGOT/SGPT < 2 times upper limit of normal) and renal function ( creatinine < 2 mg/dl)

• Adequate cardiac function (left ventricular ejection fraction [LVEF] > 50%).

• Informed consent

• Histologically or cytologically confirmed breast adenocarcinoma

• Prior surgical excision of the primary breast tumor

• Prior completion of standard adjuvant chemotherapy and/or radiotherapy

• Locally advanced disease after the completion of neo-adjuvant chemotherapy, surgical excision and radiotherapy provided that there was no evidence of local or metastatic disease

• Absence of any clinical or laboratory evidence of metastatic disease

• Detection of CTCs and/or DTCs (when it could be feasible) before the initiation and/or after the completion of adjuvant chemotherapy and/or radiotherapy

• Expression of HER2/c-neu on the primary tumor is not mandatory

Exclusion Criteria:

• Other invasive malignancy within the past 5 years except nonmelanoma skin cancer

• Other concurrent uncontrolled illness

• Psychiatric illness or social situation that would preclude study compliance

• Pregnant or nursing

• Positive pregnancy test

• History of allergic reaction attributed to trastuzumab (HERCEPTIN)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Trastuzumab
Trastuzumab,first administration at the dose of 8mg/Kg IV, subsequent administrations at the dose of 6mg/Kg IV,every 3 weeks for 6 cycles

Locations

Country	Name	City	State
Greece	University Hospital of Crete	Heraklion	Crete

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital of Crete

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compare the disease-free interval of patients with early-stage breast cancer		3 years	No
Secondary	Elimination of CK-19 mRNA-positive CTCs.		Assessment of CK-19 mRNA CTCs every 3 months	No